iPSC Reprogramming for Regenerative Medicine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The progress of embryonic stem cell-based therapies is hindered by immune rejection and ethical concerns, limiting their widespread availability and application in regenerative medicine.
Innovation Solution
The development of induced pluripotent stem cell (iPSC) technology, which involves obtaining human postnatal tissue samples, generating iPSCs by forcing expression of specific polypeptides like Oct3/4, Sox2, and c-Myc, and differentiating them into various cell types, offers a regenerative medicine business model that minimizes immunological rejection and ethical issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic stem cells are used for regenerative therapy, then the potential to generate diverse cell types is improved, but immune rejection and ethical concerns worsen
Solution Approach 1:
The patent uses induced pluripotent stem cells (iPSCs) as a copy or alternative to embryonic stem cells. iPSCs are generated by reprogramming adult somatic cells to express pluripotency markers (Oct3/4, Sox2, Klf4, c-Myc), creating cells with similar regenerative potential to ESCs but without the immune rejection and ethical issues. This copying approach resolves the contradiction by providing an alternative cell source that maintains versatility while eliminating harmful factors.
2Adaptability or versatility
If embryonic stem cells are used for regenerative therapy, then the potential to generate diverse cell types is improved, but ethical and legal concerns worsen
Solution Approach 1:
The patent replaces embryonic stem cells with induced pluripotent stem cells as an ethically acceptable alternative. iPSCs are generated from adult patient cells through forced expression of specific transcription factors, avoiding the destruction of embryos. This copying strategy maintains the desired cell type diversity while eliminating ethical and legal concerns associated with ESC procurement.
3Object-affected harmful factors
If induced pluripotent stem cells are generated from adult tissue samples, then immune rejection is minimized, but the complexity of the generation process increases
Solution Approach 1:
The patent breaks down the complex iPSC generation process into distinct sequential steps: (1) obtaining adult tissue samples, (2) isolating somatic cells, (3) forcing expression of pluripotency factors (Oct3/4, Sox2, Klf4, c-Myc), (4) differentiating into desired cell types, and (5) transplantation. This segmentation makes the overall complex process more manageable and controllable while achieving the goal of minimizing immune rejection through autologous cell generation.
4Object-generated harmful factors
If adult tissue samples are used to generate iPSCs, then ethical issues are resolved, but the availability of suitable samples may be limited
Solution Approach 1:
The patent demonstrates that a wide variety of adult tissue samples can serve as sources for iPSC generation, including skin biopsies, blood samples, hair follicles, and other easily obtainable tissues. This universality approach resolves the contradiction by showing that multiple different sample types can all be used to generate therapeutic iPSCs, thereby ensuring both ethical compliance and adequate sample availability for treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the large-scale generation of viable cells and tissues with minimal risk of rejection, enabling treatment of various conditions and facilitating drug screening platforms, while addressing ethical concerns associated with embryonic stem cells.
Implementation Method 1
manipulating the sample in order to force expression of: (a) one or more of the following polypeptides: Oct3/4, Sox2, Klf4, and c-Myc
Data Source
AI summary
The present disclosure features methods relating to conducting a stem cell technology business such as a regenerative medicine business based on induced pluripotent stem cells (iPSCs) and cells differentiated from iPSCs. The present disclosure also provides a database of iPSC-derived cells and methods of using the database for tracking customers and samples, as well as methods for marketing and running the business.